IPH6501 — Initial data
2026
Clinical data are expected to be presented in 2026.Source filing
IPHA biotech catalysts & pipeline
INNATE PHARMA SA · Data as of 2026-10-27
Upcoming catalysts
monalizumab — Clinical data readout
H1 2027
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously.Source filing
oleclumab — Clinical data readout
H1 2027
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously.Source filing
IPH4502 — Conference presentation
Nov 18
Initial Phase 1 dose-escalation data will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) on November 18, 2026.Source filing